Clinical Report: Optigo Wins People’s Choice Award at Eyecelerator 2025
Overview
Optigo Biotherapeutics received the People’s Choice Award at Eyecelerator 2025 for its innovative approach to long-acting intravitreal biologics. The company presented preclinical data indicating the potential for 6-month dosing intervals in treating neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).
Background
The management of nAMD, DME, and RVO often requires frequent intravitreal injections of anti-VEGF therapies, which can burden patients and affect adherence to treatment. Innovations that extend dosing intervals while maintaining efficacy are crucial for improving patient outcomes. Optigo's research focuses on bifunctional fusion proteins that could significantly reduce the frequency of injections needed for these conditions.
Data Highlights
Optigo's preclinical studies demonstrated that modified molecules linked to albumin or hyaluronan showed a 2x to 3x increase in half-life compared to aflibercept alone, remaining active for 6 months or longer without signs of inflammation.
Key Findings
- Optigo's bifunctional fusion proteins aim to prolong the half-life of anti-VEGF therapies.
- Preclinical data suggest potential for 6-month dosing intervals in nAMD, DME, and RVO.
- Modified molecules showed a 2x to 3x increase in half-life over aflibercept.
- No signs of inflammation were reported in preclinical studies, indicating a favorable safety profile.
- The approach aligns with the global need for improved patient adherence to treatment regimens.
Clinical Implications
The findings from Optigo's research could lead to significant advancements in the management of retinal diseases, potentially reducing the treatment burden on patients. If successful, longer dosing intervals may enhance patient adherence and improve overall visual outcomes.
Conclusion
Highlight the next steps in clinical trials and development to show ongoing progress.
References
- Retinal Physician, 2025 -- Optigo Wins People’s Choice Award at Eyecelerator 2025
- Eyecare Business — Transitions Optical Announces Innovation Awards Finalists
- Eyecare Business — 1/22 2023 Transitions Innovation Award Finalists Announced
- Eyecare Business — ICYMI
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
- Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.